Elsevier

European Urology

Volume 68, Issue 2, August 2015, Pages 194-195
European Urology

Platinum Priority – Editorial
Referring to the article published on pp. 186–193 of this issue
Clinical Management of Prostate Cancer in Men with BRCA Mutations

https://doi.org/10.1016/j.eururo.2014.11.005Get rights and content

Section snippets

Conflicts of interest

The authors have nothing to disclose.

References (10)

There are more references available in the full text version of this article.

Cited by (10)

  • Familial prostate cancer

    2016, Seminars in Oncology
    Citation Excerpt :

    Prostate cancer-specific survival has also been reported to be lower among screen-detected prostate cancer for individuals carrying a BRCA2 mutation compared to non-carriers (61.8% v 94.3%, P <10-4) [30]. Another study reported no significant difference in response of castrate-resistant prostate cancer to taxane-based therapy between BRCA mutation carriers versus non-carriers in an Ashkenazi Jewish population [87], providing further insight into potential systemic treatment for prostate cancer patients carrying BRCA mutations. While genetically-based treatment guidelines do not currently exist for prostate cancer, expert opinion is emerging regarding how to consider individualizing management [88].

  • Genetics of prostate cancer

    2019, Journal fur Urologie und Urogynakologie
View all citing articles on Scopus
View full text